CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.57B, above the global median of $1.18B
- PositionProfit margin is 69.6%, higher than 95% of its Biotechnology peers (median -32.5%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.14%
Annual Rate
CNY 0.47Paid semi-annual
Payout Ratio
13.8%Sustainable
Payback Period
87.6 yr
Last Ex-Dividend
Jun 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
37.33BCNY5.57B · vs all stocks (USD)
Trailing P/E
11.80xvs Biotechnology peers
Revenue (TTM)
4.42BCNY660.19M · vs all stocks (USD)
Profit Margin
69.65%vs Biotechnology peers
Beta
0.3440xvs all stocks
52-Week Change
7.88%vs all stocks
Market Capitalization
37.33BCNY5.57B · vs all stocks (USD)
Enterprise Value
30.97BCNY4.62B · vs all stocks (USD)
Trailing P/E
11.80xvs Biotechnology peers
Forward P/E
48.77xvs Biotechnology peers
Price to Sales (TTM)
8.20xvs Biotechnology peers
Price to Book (MRQ)
4.27xvs Biotechnology peers
Enterprise to Revenue
7.00xvs Biotechnology peers
Enterprise to EBITDA
9.03xvs Biotechnology peers
Gross Margin
80.25%vs Biotechnology peers
Profit Margin
69.65%vs Biotechnology peers
Operating Margin
29.47%vs Biotechnology peers
Return on Assets (TTM)
27.84%vs Biotechnology peers
Return on Equity (TTM)
43.53%vs Biotechnology peers
Revenue (TTM)
4.42BCNY660.19M · vs all stocks (USD)
Revenue per Share (TTM)
4.95CNYUpdated Sep 22, 2026Quarterly Revenue Growth
31.30%vs Biotechnology peers
Gross Profit (TTM)
4.11BCNY613.83M · vs all stocks (USD)
EBITDA (TTM)
3.39BCNY506.43M · vs all stocks (USD)
Net Income (TTM)
3.08BCNY459.80M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
121.10%vs Biotechnology peers
Operating Cash Flow (TTM)
2.79BCNY416.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.68BCNY250.39M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4728CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.14%vs all stocks
Payout Ratio
13.79%vs Biotechnology peers
Minority Interest (Equity)
-38.21MCNYFY2025 · Dec 31, 2025Revenue
4.20BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
332.95MCNYFY2025 · Dec 31, 2025Gross Profit
3.87BCNYFY2025 · Dec 31, 2025Operating Income
3.16BCNY471.30M · vs all stocks (USD)
Pre-tax Income
3.32BCNYFY2025 · Dec 31, 2025Income Tax Expense
426.68MCNYFY2025 · Dec 31, 2025Net Income
2.89BCNYFY2025 · Dec 31, 2025EBIT
3.32BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.39BCNYFY2025 · Dec 31, 2025Research & Development
434.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
172.14MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.69MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
84.32MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
569.40KCNYFY2025 · Dec 31, 2025EPS (Basic)
4.70CNYFY2025 · Dec 31, 2025EPS (Diluted)
4.68CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
616.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
616.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.89BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
7.45MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.86BCNYFY2025 · Dec 31, 2025Free Cash Flow
2.61BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
67.25MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.89BCNYFY2025 · Dec 31, 2025Stock-based Compensation
26.46MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-54.60MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
23.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.65MCNYFY2025 · Dec 31, 2025Capital Expenditures
-252.95MCNYFY2025 · Dec 31, 2025Purchase of Investments
-18.58BCNYFY2025 · Dec 31, 2025Sale of Investments
15.67BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.16BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-50.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-76.46MCNYFY2025 · Dec 31, 2025Other Financing Charges
15.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-111.07MCNYFY2025 · Dec 31, 2025Shares Outstanding
896.23MSharesUpdated Sep 22, 2026Float Shares
138.48MSharesUpdated Sep 22, 2026% Held by Insiders
84.44%vs all stocks
% Held by Institutions
5.43%vs all stocks
Total Cash (MRQ)
5.27BCNY785.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.88CNYUpdated Sep 22, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
25.60xvs Biotechnology peers
Book Value per Share (MRQ)
9.49CNYUpdated Sep 22, 2026Total Assets
8.96BCNY1.34B · vs all stocks (USD)
Total Current Assets
6.23BCNYFY2025 · Dec 31, 2025Total Liabilities
542.62MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.73BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
95.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
447.02MCNYFY2025 · Dec 31, 2025Cash
193.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
193.27MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.07BCNYFY2025 · Dec 31, 2025Accounts Receivable
150.07MCNYFY2025 · Dec 31, 2025Inventory
260.55MCNYFY2025 · Dec 31, 2025Accounts Payable
34.96MCNYFY2025 · Dec 31, 2025Common Stock (Book)
618.09MCNYFY2025 · Dec 31, 2025Retained Earnings
5.15BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.41BCNY1.26B · vs all stocks (USD)
52-Week Low
34.34CNYUpdated Sep 22, 202652-Week High
66.62CNYUpdated Sep 22, 202652-Week Change
7.88%vs all stocks
Beta
0.3440xvs all stocks
50-Day MA
44.00CNYUpdated Sep 22, 2026200-Day MA
45.17CNYUpdated Sep 22, 2026Avg 10-Day Volume
5.06MSharesUpdated Sep 22, 2026Avg 30-Day Volume
8.67MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
3.43CNYUpdated Sep 22, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 69.6%, higher than 95% of its Biotechnology peers (median -32.5%)Significant
Profit margin: 0.70Industry median: -0.32Industry P95: 0.39Peers compared: 193
Return on equity is 43.5%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 0.44Industry median: -0.24Industry P95: 0.23Peers compared: 193
Return on assets is 27.8%, higher than 95% of its Biotechnology peers (median -21.2%)Significant
Return on assets: 0.28Industry median: -0.21Industry P95: 0.19Peers compared: 193
Current ratio is 25.6×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 25.60Industry median: 5.28Industry P95: 22.31Peers compared: 193
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.99
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.57B, above the global median of $1.18BNotable
Market cap (USD): 5,571,919,081.495Global Median: 1,180,223,658.953
Revenue is $660.19M, above the global median of $548.88MNotable
Revenue (USD): 660,192,559.713Global Median: 548,883,780.48
Levered free cash flow is $250.39M, above the global median of $18.73MNotable
Levered free cash flow (USD): 250,389,500.824Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Suzhou TFC Optical Communication Co., Ltd.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Shanghai Bochuan Electronic Co., Ltd.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin